Browse News
Filter News
Found 22 articles
-
DNA Synthesis Market Size, Share, Trends, Growth, Report 2022-2030
10/25/2022
According to Latest Report Study, the global DNA synthesis market was surpassed at USD 260.7 million in 2021 and is expected to hit around USD 513.80 million by 2030, growing at a CAGR of 7.83% from 2022 to 2030.
-
MDimune and SensoryCure announce a collaboration to develop therapeutics for hearing loss
10/24/2022
MDimune, Inc., a Korean biotech company developing BioDroneTM platform technology based on cell-derived vesicles (CDVs), enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss.
-
Insufflation Devices Market Size to Hit US$ 5.76 BN by 2030
5/13/2022
Increasing adoption of minimally invasive surgeries, rapidly aging population, and rising number of laparoscopic procedures are among the major factors driving this market’s growth.
-
Anatomic Pathology Market Size to Hit US$ 40.66 Bn by 2030
5/3/2022
The global anatomic pathology market size is expected to hit around US$ 40.66 billion by 2030 from valued at US$ 17.06 billion in 2020 with a CAGR of 11.08% during forecast period 2021 to 2030.
-
Radionetics Oncology Appoints Nishan de Silva, M.D. as Chief Executive Officer
4/12/2022
Radionetics Oncology announced today the appointment of Nishan de Silva, M.D. as its Chief Executive Officer.
-
RFID in Healthcare Market Size to Hit US$ 12 Billion by 2027
3/8/2022
The global RFID in Healthcare market size is predicted to hit around US$ 12 billion by 2027 and poised to grow at a remarkable CAGR of 21% during the forecast period 2022 to 2027.
-
AFYX Therapeutics Presents New Study Showing Therapeutic Antibody Delivery to Oral Mucosa Using Rivelin Biodegradable Mucoadhesive Patch
9/7/2021
AFYX Therapeutics announced results from a preclinical study from the company’s collaboration with the University of Sheffield in the UK exploring the potential effects of delivering antibody fragments directly to inflamed tissue in mucosal diseases using Rivelin® technology.
-
Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
-
BioSpace Movers & Shakers, June 25
6/25/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
6/24/2021
Selecta Biosciences, Inc. today announced the appointment of Nishan de Silva, M.D. to its Board of Directors.
-
CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical OfficerExperienced Biotech Executive, Physician-Scientist and Orphan Disease Expert to Lead Clinical/Medical Functions as Seladelpar Advances in Phase 3 and as Pipeline Programs Mature
5/13/2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that medical and clinical leader Dennis D. Kim, MD, MBA, is joining the company as Chief Medical Officer.
-
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
AFYX Therapeutics Presents Phase 2 Data of Rivelin-CLO at 2021 AAOM Virtual Conference
4/15/2021
AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced Phase 2 clinical efficacy and safety data of Rivelin ® Clobetasol (“Rivelin-CLO”), a novel mucoadhesive
-
Study Published in the European Journal of Oral Sciences Features AFYX Therapeutics’ Rivelin-CLO Patch for the Treatment of Oral Lichen Planus
3/11/2021
AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that a study of the Rivelin® Clobetasol patch (“Rivelin-CLO”), a novel adhesive patch technology designed to deliver a therapeutic agent to wet tissue surfaces, was featured in the March issue of The European Journal of Oral Sciences.
-
AFYX Therapeutics Appoints Dennis Kim, M.D., MBA, as Chief Medical Officer
11/18/2020
AFYX Therapeutics ("AFYX"), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced the appointment of Dennis D. Kim, M.D., MBA, as chief medical officer.
-
Clinical Catch-Up: April 20-24
4/27/2020
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look. -
AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus
4/22/2020
AFYX Therapeutics ("AFYX"), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin ® Clobetasol patch ("Rivelin-CLO") met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus ("OLP"). In t
-
Novo Seeds expands company formation activities at BiOrigin with seasoned entrepreneurs
11/26/2019
Novo Seeds, the early stage investment arm of Novo Holdings, wholly owned by the Novo Nordisk Foundation, announced that its advisory unit, BiOrigin, has appointed several seasoned entrepreneurs to its team.
-
AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress
10/9/2019
AFYX Therapeutics announced results from a Phase 1 clinical proof of concept study evaluating the use of the Rivelin® bio-adhesive patch in patients with vulvar lichen sclerosus, a painful genital skin condition that affects up to 3% of post-menopausal women.
-
AFYX Therapeutics Closes $13 Million Convertible Loan Financing
6/24/2019
Funds support the completion of ongoing Phase 2b study in Oral Lichen Planus